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SUMMARY 
 
Aims 
Blood flow generates wall shear stress (WSS) which has profound effects on endothelial cell 
(EC) function. Low WSS promotes vascular inflammation and atherosclerosis whereas high 
uniform WSS is protective. Ivabradine decreases heart rate by inhibiting the If current in the 
sinus node leading to altered hemodynamics but unaltered blood pressure. Besides its 
cardio-protective effects, ivabradine protects arteries from inflammation and atherosclerosis 
via unknown mechanisms. Here we hypothesised that ivabradine protects arteries by 
increasing WSS to reduce vascular inflammation.  
 
Methods and Results 
Hypercholesterolemic mice (low-density lipoprotein receptor–deficient) were treated with 
ivabradine for 7 weeks in drinking water or remained untreated as a control. En face 
immunostaining and confocal microscopy demonstrated that treatment with ivabradine 
reduced the expression of pro-inflammatory VCAM-1 (p<0.01) and enhanced the expression 
of anti-inflammatory eNOS (p<0.01) at the inner curvature of the aorta. We concluded that 
ivabradine alters EC physiology indirectly via modulation of flow because treatment with 
ivabradine had no effect in ligated carotid arteries in vivo, and did not influence the basal or 
TNF-induced expression of inflammatory (VCAM-1, MCP-1) or protective (eNOS, HMOX1, 
KLF2, KLF4) genes in cultured EC. We therefore considered whether ivabradine can alter 
WSS which is known to regulate EC inflammatory activation. Computational fluid dynamics 
demonstrated that ivabradine treatment reduced heart rate by 20% (p<0.05) and enhanced 
WSS in the aorta.  
 
Conclusions  
We conclude that ivabradine treatment altered hemodynamics in the murine aorta by 
increasing the magnitude of shear stress. This was accompanied by induction of a 
mechanosensitive protective gene (eNOS) and suppression of inflammatory VCAM-1, 
whereas ivabradine did not alter EC that could not respond to flow. Thus ivabradine protects 
arteries by altering local mechanical conditions to trigger an anti-inflammatory response. 
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INTRODUCTION 
Heart rate is an important risk factor and therapeutic target in cardiovascular disease1-6. 
Elevated heart rate was associated with poor cardiovascular outcome in patients with heart 
failure or acute myocardial infarction 1, 2. Correspondingly, interventions that lowered resting 
heart rate led to protection from experimental atherogenesis 5, 6 and reduced infarct size and 
mortality rates in patients with acute myocardial infarction3. A beneficial effect of heart rate 
reduction on coronary artery disease was also demonstrated in clinical trials using 
ivabradine. This compound decreases heart rate by inhibiting the If current in the sinus node, 
without affecting blood pressure or systolic ventricular function. Ivabradine treatment 
improved prognosis in patients with chronic heart failure7 and had anti-ischemic effects in 
patients with stable angina 8. Moreover, ivabradine was associated with a reduction in 
coronary endpoints in coronary artery disease patients with left ventricular dysfunction and 
heart rate 70 bpm9. Despite this, a recent study found that ivabradine did not have 
beneficial effects in patients with stable coronary artery disease but without heart failure 10, 
suggesting that its vasculoprotective effects may be restricted to patients with heart failure. 
The mechanism for the protective effects of ivabradine has been studied using animal 
models 11-14. The administration of ivabradine reduced experimental atherosclerosis in 
hyperlipidaemic murine 13 and rabbit models 14. However, molecular targets of ivabradine 
have not been identified in vascular cells and the atheroprotective effects of ivabradine are 
not due to a lipid-lowering effect of ivabradine, since the drug had no effects on cholesterol 
levels 11-13. Taken together, these experiments suggest that a direct effect of ivabradine on 
vessels is unlikely, and suggest that reduction of heart rate may be a primary mechanism of 
action of the drug. 
 
Arteries are exposed to mechanical forces including mechanical wall stress (tangential, 
longitudinal or circumferential) and blood-flow induced wall shear stress (WSS) that play 
important roles in vascular homeostasis and disease. Indeed, although atherosclerosis is 
associated with systemic risk factors, such as hypercholesterolemia, it develops 
preferentially at branches and bends of the arterial tree that are exposed to complex patterns 
of blood flow 15, 16. Computational fluid dynamic (CFD) studies have demonstrated that the 
magnitude of WSS (time-averaged WSS (TAWSS) over the cardiac cycle) is lower at 
atherosclerosis-prone sites exposed to complex flow compared to regions that are 
protected17, 18. Low WSS promotes atherosclerosis by inducing endothelial expression of 
inflammatory molecules (e.g. VCAM-1) that promote lesions19-21, whereas high unidirectional 
WSS induces anti-inflammatory genes such as eNOS22. Although ivabradine is known to 
increase stroke volume and coronary perfusion23, its effects on WSS have not been studied. 
Here we tested the hypothesis that ivabradine protects arteries by enhancing WSS which 
reduces inflammatory activation of arterial EC. 
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MATERIAL AND METHODS 
Animals, surgery, ivabradine treatment and diet 
All experiments conform to the guidelines laid out in the UK Animals Scientific Procedures 
Act (1986) and to the guidelines from Directive 2010/63/EU of the European Parliament on 
the protection of animals used for scientific purposes, and were performed under a project 
license from the UK Home Office. LDLR-/- (low-density lipoprotein receptor–deficient) mice 
on a C57BL/6 genetic background were obtained commercially from Jackson laboratories 
and then bred in-house. All mice used in this study were male. Mice were housed under 
specific-pathogen free conditions. Where indicated, mice of 8 weeks of age were 
anaesthetized using a mixture of ketamine, xylazine and atropine prior to surgical exposure 
of the carotid arteries. The right carotid artery was ligated using cotton thread immediately 
proximal to the carotid bifurcation. Mice were allowed to recover for 1 week prior to 
experimentation. Some animals were treated with ivabradine either by i.v. injection (5 mg/kg) 
or in drinking water ad libitum (162 mg/L for 1 or 7 weeks). Alternatively, mice remained 
untreated as a control. Where indicated, normal chow diet was replaced at 10 weeks of age 
with Diet W; a cholate-free high-fat Western-type diet (Arieblok Diet W, 4021.06; Woerden, 
Netherlands) for 6 weeks. The Diet W (high-fat diet) consisted of (w/w) Cocoa butter (15%), 
cholesterol (0.25%), sucrose (40.5%), cornstarch (10%), corn oil (1%), cellulose (5.95%), 
casein (20%), 50% choline chloride (2%), methionine (0.2%) and mineral mixture (5.1%), 
total fat content (16%).  
 
En face staining. Animals were killed using pentobarbital (800 mg/kg by intraperitoneal 
injection). Endothelial expression of VCAM-1 or eNOS was determined by en face staining of 
the murine aorta as described21. Briefly, aortae were perfusion fixed and isolated prior to 
permeabilisation using 0.5% Triton X-100 (Sigma-Aldrich), and blocking with 20% goat 
serum for 2 h at room temperature. After washing with phosphate-buffered saline, the tissue 
was incubated with anti-VCAM-1 (EPR505; Novus Biologicals UK) or anti-eNOS (BD 
Bioscences) primary antibodies overnight at 4 °C. The tissue was then washed with PBS 
and incubated with goat anti-rabbit IgG antibody conjugated to AlexaFluor-568 (A11036; 
Invitrogen) for 2-3 h at room temperature followed by incubation with AlexFlour-488 labelled 
anti-CD31 antibody (102514; BioLegend) for 72-120 h at 4°C. The tissue was incubated with 
TOPRO-3 to counterstain nuclei. To control for specific binding, tissues were incubated with 
irrelevant rabbit IgG antibodies and appropriate fluorescent secondary antibodies, or were 
incubated with secondary antibodies alone. The ascending aorta and arch were mounted 
and images of the EC monolayer were obtained using an inverted laser-scanning confocal 
microscopy (LSM 510 Meta inverted; Zeiss, Oberkochen, Germany). Protected (outer 
curvature) and susceptible (inner curvature) regions of the aortic arch were located using 
anatomical landmarks as described21. The mean expression levels of VCAM-1 and eNOS 
were determined by pooling mean fluorescence values from multiple cells (> 50 cells per 
field of view).  
 
EC culture and exposure to shear stress. Human umbilical vein EC (HUVEC) were 
isolated using collagenase digestion and cultured. EC at passage 3-5 were cultured until 
confluent in 6 well plates and exposed to flow using an orbital shaking platform (PSU-10i; 
Grant Instruments) housed inside a cell culture incubator24. The radius of orbit of the orbital 
shaker was 10 mm and the rotation rate was set to 210 rpm. This system generated low 
shear stress (approximately 5 dyn/cm2) with rapid variations in direction in the centre and 
high shear stress (approximately 15 dyn/cm2) with relatively uniform direction at the 
periphery24.  
 
Comparative real time PCR. The levels of transcripts were assessed using quantitative real 
time PCR (qRT-PCR) as described 19, 24 using gene-specific primers (Supplementary Table 
1). Relative gene expression was calculated by comparing the number of thermal cycles that 
were necessary to generate threshold amounts of product. Fold changes were calculated 
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using the ΔΔCt method. 
 
Vascular geometry and heart rate measurements 
Heart rate and blood pressure were measured in conscious, restrained LDLR-/- mice using a 
commercial automated system Visitech Systems, Apex, NC. In order to familiarize mice to 
this procedure, daily measurements were carried out for two weeks prior to experimentation. 
Mean blood pressure and heart rate values were generated by pooling data from 20 
measurements. 
 
CT angiography was carried out as described (Inveon, Siemens)25. Electrocardiogram gating 
was used to minimize movement artefacts caused by the movement of the heart and of the 
vessel during the cardiac cycle. Thus all images were acquired at the same time point of the 
cycle, the end of diastole, to avoid scanning during the dilation of the aorta during systole. 
Transthoracic echocardiography was carried out using a commercial system (Vevo 770® 
with a RMV707B scan head, Visual Sonics, Toronto, Canada) as described26. Briefly mice 
were anaesthetised with isoflurane via oxygen before being placed supine on a heated 
platform and covered to minimise heat loss. Maintenance Isoflurane (0.5-1.5%) with oxygen 
was delivered via a nose cone. Following depilation, Doppler pulse wave velocities were 
captured from peak flow in the ascending aorta. Data were averaged from 3-5 
measurements per mouse. 
 
Computational fluid dynamics (CFD) 
The triangulated lumen surface was imported into ANSYS ICEM-CFD to generate a high 
quality hybrid tetrahedral mesh with prismatic boundary layer. The use of a prismatic layer of 
4 cells allows for accurate representation of the WSS using a low overall cell count. 
Preliminary grid sensitivity studies using grid sizes from 80,000 to 500,000 cells showed that 
the results for WSS were grid insensitive within 2% for a grid size of approximately 200,000 
cells while allowing for low simulation times of approximately 8 h on 2 cores of a 2.5GHz 
Intel i7 processor. 
 
The unsteady Navier-Stokes equations were solved numerically using the finite volume 
method (FVM) in ANSYS FLUENT 14.5. The vessel geometry was assumed to be rigid. 
Blood was modelled as a Newtonian fluid with a dynamic viscosity of  (4 cP) 
and a density of . Using a typical maximum flow speed at the aortic root  
and the hydraulic diameter of , the maximum Reynolds number is 
 
The flow was therefore modelled as laminar.  
 
The aortic root cross section was extruded by 10 diameters to allow for development of the 
flow and prescription of a Dirichlet inlet boundary condition for the normal velocity as a plug 
profile at the extruded section. The time dependent mean velocity was digitized from the US 
Doppler images and a 3rd order Bezier approximation27 was used to generate a second-
order-smooth mean velocity curve. 
 
At the exit of the aorta descendens and the branches a Neumann outlet boundary condition 
was used with a flow split of 70, 16, 8 and 6 percent for aorta descendens, innominate, 
common carotid and subclavian, respectively.  
 
Numerical solutions were obtained using cell based higher with second order pressure, 
quadratic upwind momentum and second order implicit time discretization. Time step size 
was chosen as 1/400th or 1/600th of the cycle time for the control and ivabradine cases, 
respectively, maximum Courant numbers were below 8. In addition to the solution vector, 
three dimensional WSS data for the aorta and the defined ROI at the outer and inner 
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curvature were area-averaged during run time. From the time-dependent WSS, the time-
averaged WSS at the wall was calculated: 
 
 
 
 
 
Statistics   Differences between samples were analysed using an unpaired or paired 
Student’s t-test, one-way ANOVA with Bonferroni’s adjustment, or two-way ANOVA with 
Sidak’s multiple comparison test. 
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RESULTS 
Ivabradine reduced inflammation of arterial EC.  
We hypothesized that ivabradine protects rodent arteries by reducing inflammatory activation 
of EC. This was assessed using LDLR-/- mice exposed to a high fat diet for 6 weeks, a 
regime that is known to generate hypercholesterolemia and inflammatory activation of aortic 
EC28. In the first instance, we investigated whether oral ivabradine can reduce heart rate in 
LDLR-/- mice. Male LDLR-/- mice were exposed to ivabradine in drinking water for 7 weeks or 
were exposed to untreated water as a control (Fig. 1A). The average consumption of water 
in ivabradine-treated and control groups was similar (4.85 versus 5.27 ml/day/animal, 
respectively) and it was calculated that treated animals consumed an average of 27 mg/kg 
ivabradine daily. Pressure cuff measurements revealed that treatment with ivabradine 
reduced heart rate by approximately 20% but did not influence systolic or diastolic blood 
pressure (Fig. 1B). Thus although ivabradine was administered to LDLR-/- mice at doses 
significantly greater than those used clinically (0.25-0.33 mg/kg/day7-9) it caused a reduction 
in heart rate that was proportional to that observed clinically7-9. 
 
We examined whether reduced heart rate in ivabradine-treated mice was associated with an 
altered inflammatory profile using en face staining to quantify endothelial expression of 
molecules with inflammatory (VCAM-1) or anti-inflammatory (eNOS) function. In untreated 
mice, VCAM-1 expression in EC was significantly higher at the inner compared to the outer 
curvature (Fig. 2, left panels), whereas eNOS expression was comparable at the inner and 
outer curvature (Fig. 3, left panels). Treatment with ivabradine significantly reduced VCAM-1 
expression and simultaneously increased eNOS expression at both the inner and outer 
curvatures demonstrating that ivabradine reduced inflammation in aortic EC (Figs. 2 and 3, 
compare left and right panels). Thus we conclude that ivabradine exerts anti-inflammatory 
effects in the murine aorta by inducing eNOS and by suppressing VCAM-1. 
 
Ivabradine did not have direct pharmacological effects on EC.  
We wished to know whether ivabradine reduces vascular inflammation directly by 
pharmacological modification of EC or whether it acts indirectly by altering heart rate and 
hemodynamics. To address this, we exposed cultured HUVEC to ivabradine and determined 
the expression of inflammatory and anti-inflammatory genes. HUVEC were cultured under 
shear stress for 72 h using an orbiting 6-well plate system that generates low mean shear 
stress at the centre, and high mean shear stress at the periphery. They were simultaneously 
exposed to ivabradine at concentrations that mimic those detected in plasma in ivabradine-
treated mice (5-50 ng/ml). Some cultures were subsequently treated with the 
proinflammatory cytokine TNF to determine the effect of ivabradine on inflammatory 
responsiveness. qRT-PCR revealed that the expression of the inflammatory effector 
molecules VCAM-1 and MCP-1 was enhanced in EC exposed to low compared to high 
WSS, and that anti-inflammatory eNOS, HMOX1, KLF2 and KLF4 displayed the opposite 
pattern (Fig. 4). The application of TNF enhanced the expression of VCAM-1 and MCP-1 
but reduced the expression of eNOS and KLF2. Notably, treatment of EC with ivabradine 
had no effect on the flow-induced alterations of VCAM-1, MCP-1, eNOS, HMOX1, KLF2 or 
KLF4 expression and did not influence TNF-mediated induction of VCAM-1 or MCP-1. 
Thus we conclude that ivabradine does not alter EC inflammatory or protective responses 
directly. 
 
The potential ability of ivabradine to alter EC directly was also studied by ligating carotid 
arteries in LDLR-/- mice so that EC were exposed to static conditions. After carotid artery 
ligation, mice were exposed to ivabradine for 7 weeks (in drinking water as above) or to 
untreated water as a control. En face staining revealed that eNOS expression was negligible 
in ligated arteries of control- or ivabradine-treated animals (Supplementary Figure). This 
observation is consistent with previous reports that eNOS is shear-sensitive22 and indicates 
that ivabradine does not induce eNOS expression in EC directly via a pharmacological 
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effect. In summary, ivabradine had anti-inflammatory effects in the aorta which is exposed to 
flow but did not influence EC in cultured EC or cuffed arteries exposed to static conditions. 
Thus we conclude that ivabradine does not alter EC activation directly. Instead, our data are 
consistent with the hypothesis that ivabradine reduces inflammation of arteries by altering 
hemodynamics.  
 
Heart rate reduction by ivabradine increased average wall shear stress. 
Next, we tested the hypothesis that ivabradine protects atheroprone sites by increasing the 
magnitude of WSS. This was studied by CFD, which relies on accurate measurement of 
vascular geometries and blood flow velocities. WSS is sensitive to changes in vascular 
diameter since it is inversely proportional to the vessel radius cubed. Because of this we 
examined whether treatment of mice with ivabradine altered the geometry of the aorta. MRI 
revealed that exposure of mice to ivabradine for 7 weeks (in drinking water as above) did not 
influence the diameter of the ascending thoracic aorta (X+/-Y versus Z+/-Q; p>0.1) or aortic 
arch (………). We next assessed the effects of ivabradine on blood flow velocities which 
were measured by transthoracic echocardiography. Since mice were anesthetised for this 
procedure, ivabradine was administered by intra-venous injection to ensure high precision in 
dose and timing. We wished to achieve a heart rate reduction of approximately 20% since 
this is similar to the reduction observed in mice used for assessment of inflammation (Fig. 
1B). Using varying doses of ivabradine (0.5, 5 or 15 mg/kg) we observed that ivabradine 
reduced heart rate in a dose-dependent manner (Fig. 5A). Subsequent studies of the effects 
of ivabradine on blood flow were carried out using 5 mg/kg ivabradine because this dose 
achieved an approximate 20% reduction in heart rate (Fig. 5A). We observed that ivabradine 
treatment significantly altered blood flow velocity in the ascending aorta by enhancing both 
the peak velocity and the average velocity over the cardiac cycle (Fig. 5B). Unsteady CFD 
simulations were then performed using time-varying waveforms from ivabradine-treated 
versus control animals as inlet boundary conditions and a single representative geometry. 
The kinetic changes in WSS magnitude were determined over the cardiac cycle for 
anatomically-distinct portions of the aortic arch.  At the inner curvature WSS displayed a 
transient peak followed by a rapid decline in magnitude (Fig. 5C). By contrast, WSS 
magnitude declined less rapidly following systole in the outer curvature and was therefore 
higher in the outer compared to the inner curvature for most of the cardiac cycle (Fig. 5C). 
Consistent with this, mapping of time-averaged WSS onto the geometry of the aortic arch 
revealed higher values at the outer compared to the inner curvature (Fig. 6, left panels) as 
described17, 29, 30. Treatment with ivabradine generated a prolonged higher flow rate in the 
aorta after systole leading to a prolonged higher level WSS (Fig. 5C) and thus an enhanced 
time-averaged WSS at both the inner and outer curvatures (Fig. 6, compare left and right 
panels). These data linking reduced EC inflammatory activation with enhancement in time-
averaged WSS in response to ivabradine are consistent with the hypothesis that ivabradine 
reduces inflammation in the aortic arch by enhancing the magnitude of WSS. 
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DISCUSSION 
Ivabradine treatment has been used successfully to treat coronary artery disease8, 9 and can 
also reduce atherosclerosis in experimental models11-13. In particular, ivabradine prevented 
renal and cerebral endothelial dysfunction in a mouse transgenic model of mild 
dyslipidaemia11 and prevented atherosclerotic lesion formation13 and improved erectile 
function12 in hypercholesterolemic ApoE-/- mice. The underlying mechanism has remained 
elusive because ivabradine-targets have not been identified in vascular cells and ivabradine 
did not influence plasma lipid levels11, 13. Given that ivabradine alters heart rate, stroke 
volume and coronary perfusion, we tested the hypothesis that ivabradine may exert 
protective effects of arteries indirectly by altering hemodynamics which has been tightly 
linked to cardiovascular disease15-18. Our study demonstrated that ivabradine significantly 
altered flow in the murine aorta leading to enhanced WSS magnitude at both atheroprone 
and atheroprotected sites. Ivabradine induced protection from inflammation in the aorta 
(exposed to flow) but did not alter the inflammatory state of EC in conditions where flow was 
unaltered (either in vitro or in vivo), providing strong evidence that ivabradine functions 
indirectly via alteration of vascular mechanics. This is consistent with in vitro studies showing 
that VCAM-1 expression correlates inversely with shear stress magnitude31.  
 
Although it is well established that flow influences vascular function and disease, the relative 
contributions of WSS and mechanical wall stress remain uncertain. This is exemplified by a 
study by Bolduc et al32 which compared the effects of heart rate reduction  with ivabradine or 
metoprolol ( blocker) on arterial physiology and plaque development in 
hypercholesterolemic mice. In that study, although metoprolol and ivabradine had similar 
effects on heart rate reduction, ivabradine restored vascular function in cerebral arteries and 
reduced aortic plaque growth more effectively than metoprolol. Thus heart rate reduction per 
se was not sufficient to explain all of the vasculoprotective effects of ivabradine which must 
rely on other factors. Our observations provide a possible explanation for the enhanced 
protective effects of ivabradine in cerebral arteries and the aorta since this compound 
enhanced WSS which is known to have protective effects in the vasculature. On the other 
hand, Bolduc et al32 found that ivabradine and metoprolol reduced carotid artery stiffness to 
a similar degree and suggested that this was due to reduced mechanical wall stress as a 
result of lowered heart rate. Collectively, these and our own observations suggest that 
ivabradine can modulate vascular function by altering mechanical stress as well as WSS. 
Moreover, the importance of these factors may vary according to anatomical site and 
physiological context e.g. altered mechanical wall stress may be more important at proximal 
sites and in less compliant arteries. 
 
The effects of ivabradine on cardiovascular hemodynamics and physiology partially mimic 
protection afforded by physical exercise which can also lower resting pulse rate and 
enhance stroke volume23. In clinical studies, exercise at 140-180% above resting heart rate 
enhanced peak blood flow velocity and increased WSS in the aorta33, 34. Bolduc et al32 
compared the effects of ivabradine and physical exercise in hypercholesterolemic mice and 
found that while increased exercise and ivabradine both normalised cerebral artery function, 
only ivabradine reduced carotid artery stiffness. Further studies are required to determine 
whether the differential effects of these interventions on carotid and cerebral artery 
physiology are due to different effects on WSS and vascular mechanical stress. 
 
The numerical model used is consistent with models used in previous studies17, 29, 30. Since 
WSS is inversely proportional to the cubed radius of the vessel, vascular remodelling in 
response to ivabradine could have major effects on WSS. However, while ivabradine 
treatment significantly enhanced arterial blood flow velocity it did not modify the geometry of 
the aorta. Because of these considerations we compared fluid dynamics of ivabradine-
treated and control mice using distinct inlet velocities (boundary conditions) applied to a 
single representative geometry. An important simplification of the numerical model was the 
use of a rigid geometry. In a detailed study of the murine aorta, Trachet et al35 demonstrate 
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that the inclusion of distensibility resulted in more realistic flow velocity waveforms using fluid 
structure interactions (FSI) compared to CFD using a rigid geometry. However, CFD and FSI 
gave similar predictions of WSS at proximal sites near the model inlet35. Because of this, we 
reason that the use of a rigid model in our simulations is justifiable because modelling is 
restricted to the aortic arch which is proximal to the flow inlet. Moreover, vascular 
distensibility may have relatively minor effects on WSS simulations in rodent vasculature 
since de Wilde demonstrated that CFD and FSI simulations were almost identical in murine 
carotid arteries36. Nevertheless, the use of a rigid geometry is a simplifying assumption that 
inevitably leads to a degree of error and prospective FSI studies should now be carried out 
to validate our observations using CFD. A second simplication concerns the physical 
properties of blood. Since blood is a highly concentrated suspension of red blood cells, it will 
exhibit non-Newtonian behaviour. However, since the level of shear rates in the murine aorta 
are relatively high, the assumption of Newtonian behaviour of blood is considered to be 
valid.  
 
Our observation that ivabradine reduces arterial expression of VCAM-1 is consistent with its 
ability to protect against atherogenesis11-13. The mechanism may involve eNOS, which was 
induced by ivabradine in our study and is known to inhibit inflammation via NO-dependent 
nitrosylation of pro-inflammatory signalling intermediaries and transcription factors22, 37. 
Notably, previous studies revealed that high WSS enhanced the expression of eNOS and 
reduced VCAM-119-22. Thus we hypothesize that ivabradine suppresses EC expression of 
VCAM-1 via WSS-dependent induction of eNOS. However, it is also plausible that the 
enhancement of WSS and/or modulation of vascular mechanical stress in response to 
ivabradine reduces inflammation via other mechanosensitive anti-inflammatory molecules 
including KLF2, Nrf2 and MKP-138, 39. 
 
In summary, we have identified a pharmacological approach using ivabradine to elevate 
WSS in the arterial tree. Altered WSS in response to ivabradine was accompanied by 
induction of a mechanosensitive protective gene (eNOS) and suppression of inflammatory 
VCAM-1. These observations demonstrate that ivabradine protects arteries by altering local 
mechanical conditions including increased WSS magnitude which triggers an anti-
inflammatory response. In addition to providing an explanation for the protective effects of 
ivabradine, our study has broader significance by suggesting that interventions that alter 
blood flow (e.g. heart rate reduction by ivabradine or exercise) protect the vasculature, in 
part, by modulating local WSS. 
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Figure 1 Ivabradine treatment reduced heart rate in a murine model. LDLR-/- mice 
aged 9 weeks were treated using ivabradine (in drinking water) or remained untreated as a 
control (n=5 per group). After 1 week, both groups of mice were exposed to a high fat diet in 
the presence of absence of ivabradine treatment. Following 6 weeks, heart rate and blood 
pressure measurements were made and EC expression of specific proteins was determined 
by en face staining. (A) An overview of the experimental approach is shown. (B) Mean heart 
rates (upper panel), systolic (centre panel) and diastolic blood pressures (lower panel) +/- 
standard deviations are shown. Differences between means were analysed using an 
unpaired Student’s t-test. n.s., non-significant. 
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Figure 2 Ivab a in  reduced endothelial expression of VCAM-1 in the murine 
aorta. LDLR-/- mice aged 9 weeks were treated using ivabradine (in drinking water) or 
remained untreated as a control (n=5 per group). After 1 week, both groups of mice were 
exposed to a high fat diet in the presence or absence of ivabradine treatment. Following 6 
weeks, VCAM-1 expression levels in EC were assessed by en face staining of the inner and 
outer curvatures (red). EC were identified by co-staining with anti-CD31 antibodies 
conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Representative images and quantitation of VCAM-1 expression (mean +/- SEM) are shown. 
Scale bar, 20 μm. Differences between means were analysed using a 2-way ANOVA. 
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Figure 3 Ivabradine induced endothelial expression of eNOS in the murine aorta. 
LDLR-/- mice aged 9 weeks were treated using ivabradine (in drinking water) or remained 
untreated as a control prior to exposure to high fat diet for 6 weeks (n=7 control group, n=8 
ivabradine group). eNOS expression levels in EC were assessed by en face staining of the 
inner and outer curvatures (red). EC were identified by co-staining with anti-CD31 antibodies 
conjugated to Alexa Fluor® 488 (green). Cell nuclei were identified using TOPRO-3 (purple). 
Representative images and quantitation of eNOS expression (mean +/- SEM) are shown. 
Scale bar, 20 μm. Differences between means were analysed using a 2-way ANOVA.  
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Figure 4 Ivabradine did not regulate inflammatory or protective gene expression 
in cultured endothelial cells. (A) HUVEC were exposed to low or high WSS for 72 h in the 
presence of varying concentrations of ivabradine (or in the absence of ivabradine as a 
control). Some cultures were subsequently exposed to TNF (10 ng/ml) from 68-72 h. The 
expression levels of specific transcripts were measured by qRT-PCR. Data were pooled 
from 3 independent experiments and mean values +/- standard errors are shown. 
Differences between means were tested using a 2-way ANOVA. 
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Figure 5 (A) LDLR-/- mice aged 9 weeks were sedated using isofluorane prior to 
assessment of baseline heart rates by transthoracic echocardiography (untreated). (A) Mice 
were treated with 0.5, 5 or 15 mg/kg ivabradine (i.v.) and heart rates were measured 15 min 
later. Data were pooled from 5 mice and mean values +/- standard deviations are presented. 
(B, C) LDLR-/- mice aged 9 weeks were sedated using isofluorane. Mice were then treated 
with ivabradine (5 mg/kg; i.v.) and repeat measurements of aortic blood flow were made 15 
min later (ivabradine). (B) Ultrasound data (left panels) were used to generate velocity 
waveforms (right panels). (C) The velocity distributions were used as boundary conditions for 
CFD assessment of the aorta. WSS was calculated over the cardiac cycle at outer and inner 
curvatures of the aorta in basal (control) and ivabradine-treated conditions. Data shown are 
representative of those generated in 5 independent experiments.  
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Figure 6 Ivabradine enhances wall shear stress in the murine aorta. LDLR-/- mice 
aged 9 weeks (n=5) were sedated prior to the assessment of blood flow velocities in the 
aorta either prior to (control) or following administration of ivabradine (5 mg/kg; i.v.). The 
velocity distributions were used as boundary conditions for CFD assessment of the aorta. 
Time-averaged WSS were calculated and mapped onto the aortic geometry. Representative 
data from 5 independent experiments are shown in two orientations (inner curvature, upper 
panels; greater curvature, lower panels). Note that the brachiocephalic and left common 
carotid arteries are hidden in the upper panels due to the orientation of the vessel. 
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